Effects of Oral, Percutaneous and Transdermal Oestrogens on Postmenopausal Bone
Osteoporosis is a serious consequence of the menopause and a major public health issue. Within the UK, unlike many European countries, there is at present no clearly defined subspecialty of metabolic bone disease. Therefore, counselling of women requesting information on osteoporosis, fracture risk and preventive measures will involve general physicians, endocrinologists, rheumatologists, orthopaedic surgeons, family doctors and gynaecologists. The latter are increasingly becoming involved because the recent Consensus Development Conference on prophylaxis and treatment of osteopoprosis concluded that oestrogens are “currently the only well established prophylactic measure that reduces the frequency of osteoporotic fractures” .
KeywordsSpinal Bone Conjugate Equine Oestrogen Natural Menopause Postmenopausal Bone Loss Ethinyl Oestradiol
Unable to display preview. Download preview PDF.
- 3.Campbell S, Whitehead MI. Potency and hepatocellular effects of oestrogens after oral, percutaneous and subcutaneous administration. In: van Keep PA, Utian W, Vermeulen A, eds. The controversial climacteric. Lancaster, MTP, 1982; 103–25.Google Scholar
- 27.Ribot C, Pouilles JM, Tremollieres F. Prevention of vertebral bone loss by transdermal 17 beta-estradiol and oral progestin: preliminary report of a 2-year controlled study. In: Whitehead MI, Schenkel L, eds. Transdermal hormone replacement. Carnforth, Parthenon Publishing, 1990; 35–42.Google Scholar
- 28.Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Transdermal administration of 17 beta-estradiol in postmenopausal women: preliminary results of a longitudinal study. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen, Osteopress APS, 1987; 546–8.Google Scholar